OSAKA, Japan, July 30, 2026
NIPRO CORPORATION has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ELISIO-HX dialyzer, effective July 28, 2026, enabling the commercial launch of its HDs (Hemodialysis powered by super high-flux membrane) approach in the United States. The newly cleared dialyzer is designed to support expanded hemodialysis (Expanded HD) by improving the removal of larger middle molecules associated with complications of end-stage kidney disease (ESKD) while remaining fully compatible with existing dialysis equipment and established clinical workflows. According to the company, ELISIO-HX integrates seamlessly into routine dialysis practice without requiring new machines or major infrastructure changes, offering healthcare providers a practical option to enhance dialysis treatment using current clinical systems.
Super High-Flux Membrane Expands Dialysis Performance
The ELISIO-HX dialyzer incorporates NIPRO’s proprietary super high-flux membrane technology, featuring a precisely engineered pore structure that extends the clearance of larger middle molecules beyond conventional high-flux dialysis while maintaining albumin retention, an important factor in preserving patient nutritional status. The company said this technology forms the foundation of its HDs platform, which aims to improve toxin removal without increasing treatment complexity. Because the dialyzer is compatible with conventional hemodialysis systems and standard clinical workflows, healthcare providers can adopt expanded hemodialysis without additional capital investment or workflow modifications. NIPRO believes this approach makes advanced dialysis therapy more accessible for a broader population of patients undergoing long-term renal replacement therapy.
Global Clinical Experience Supports U.S. Commercial Launch
NIPRO stated that the U.S. introduction of ELISIO-HX builds on extensive clinical and real-world experience across Japan, Europe, and Latin America, where the technology has already been integrated into routine dialysis care. The company said experience from multiple international healthcare systems demonstrates that HDs can be successfully implemented while maintaining existing dialysis practices. Company executives noted that FDA clearance represents a significant milestone in expanding access to enhanced dialysis technologies for one of the world’s largest hemodialysis populations. The commercialization of ELISIO-HX in the United States will begin immediately, with NIPRO working alongside dialysis providers to facilitate adoption and support implementation in everyday clinical settings.
Advertisement
FDA Clearance Expands Access to Advanced Kidney Care
With FDA 510(k) clearance, NIPRO aims to broaden patient access to expanded hemodialysis by delivering improved dialysis performance through innovative membrane engineering while minimizing operational changes for healthcare providers. The company emphasized that HDs combines enhanced removal of larger uremic toxins with compatibility across conventional dialysis systems, allowing clinicians to offer more advanced treatment without disrupting routine care delivery. As demand continues to grow for therapies that improve outcomes for patients with end-stage kidney disease, NIPRO believes its latest regulatory milestone strengthens its commitment to providing practical, clinically integrated technologies that support better long-term patient care and improve quality of life.
Source: NIPRO press release
